Petri Vainio joined EW as Managing Director in 2004 and has been leading the EW growth equity investment practice since then. He serves as the Chairman of the Firm’s Executive Committee.
Dr. Vainio has 30 years of experience as an investor in rapidly growing healthcare companies. He has invested in and served on the board of over 20 rapidly growing pharmaceutical and medical device companies which have raised over $1 billion in private growth capital and reached a total market capitalization of over $100 billion. He has led several EW growth equity investments including Biotoscana, EUSA Pharma “I” (acquired by Jazz Pharmaceuticals), EUSA Pharma “II” (acquired by Recordati), and Healthcare Brands International (acquired by Meda Pharmaceuticals). Dr. Vainio currently serves on the Board of Directors of EW portfolio companies Laboratoires Majorelle and Grundium Oy.
Prior to joining EW, Dr. Vainio spent 12 years as a General Partner of Sierra Ventures, one of Silicon Valley’s leading venture capital firms. While at Sierra, Dr. Vainio served as General Partner of five successive funds and led the Firm’s healthcare investment practice.
Dr. Vainio holds Doctor of Medicine and Doctor of Philosophy degrees from the University of Helsinki, and a Master of Business Administration degree from Stanford University.
